Sandeep Rana

7PUBLICATIONS
35CO-AUTHORS
Molecular targetsHaematological tumoursMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 25, 2024
The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax.

Alexandria P Eiken, Elizabeth Schmitz, Erin M Drengler

|Apr 30, 2024
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.

Alexandria P Eiken, Audrey L Smith, Sydney A Skupa

|Nov 14, 2023
Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity.

Richard T Eastman, Radda Rusinova, Karl F Herold

|May 30, 2023
Mycobacterium tuberculosis CitA activity is modulated by cysteine oxidation and pyruvate binding.

Rasangi Pathirage, Lorenza Favrot, Cecile Petit

|Nov 13, 2021
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase.

Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh

Pageof 2